IMR Press / EJGO / Volume 34 / Issue 5 / pii/1630906447667-364331867

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Role of surgical staging and adjuvant treatment in uterine serous carcinoma
Show Less
1 Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Weill Cornell Medical College, New York Presbyterian Hospital
2 Department of Pediatrics, Division of Infectious Diseases, Columbia University Medical Center, New York
3 Department of Pathology, Weill Cornell Medical College, New York Presbyterian Hospital, New York (USA)
Eur. J. Gynaecol. Oncol. 2013, 34(5), 453–456;
Published: 10 October 2013

Purpose of investigation: This study evaluates the association of clinical and pathologic characteristics of patients with uterine serous carcinoma (USC) with disease recurrence. Materials and Methods: Surgically-staged patients with USC at a single institution were identified and clinical and pathologic variables were compared. Results: Of the 51 patients included in this analysis, 75% percent received adjuvant chemotherapy, 51% received radiation therapy, and 47% received both. After a median follow-up of 33 months, 42% of patients had disease recurrence. On multivariable analysis, positive pelvic lymph nodes were associated with a shorter interval between surgery and recurrence: 13.6 months progression-free survival (PFS) with positive vs 17.2 months with negative lymph nodes (p = 0.05). Patients with early-stage disease who did not receive any adjuvant treatments had a significantly greater risk of disease recurrence (44.4% vs 7.70%, p = 0.043). Conclusion: In this population of surgically-staged patients with USC, pelvic lymph node metastases were predictive of a shorter PFS.
Uterine serous carcinoma
Surgical staging
Adjuvant therapy
Back to top